Novo Nordisk buys production plant in New Hampshire
27 August 2014 | By Novo Nordisk
Novo Nordisk announced the acquisition of a manufacturing facility in West Lebanon, New Hampshire, USA, from Olympus Biotech...
List view / Grid view
News
GSK receives FDA approval of an additional Promacta® (eltrombopag) indication for use in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST)
27 August 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the once-daily use of Promacta® (eltrombopag) in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy...
Tecan and RECIPE announce co-marketing agreement for automation of LC-MSMS IVD kits
26 August 2014 | By kdm communications
With clinical laboratories increasingly turning to high throughput LC-MSMS analysis, laboratory automation specialist Tecan and RECIPE Chemicals and Instruments GmbH have announced a co-marketing agreement for automation of LC-MSMS IVD kits...
Roche and InterMune reach definitive merger agreement
26 August 2014 | By Roche
Roche and InterMune, Inc. announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction...
Actavis confirms Generic Neupro® Patent challenge
26 August 2014 | By Actavis
Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr...
ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
26 August 2014 | By GlaxoSmithKline
ViiV Healthcare announced that the US Food and Drug Administration has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection...
Biogen Idec names Adriana Karaboutis EVP, Technology and Business Solutions
26 August 2014 | By Biogen Idec
Biogen Idec announced the appointment of Adriana Karaboutis as executive vice president, Technology and Business Solutions, effective September 24, 2014...
AstraZeneca announces partnership with Illumina to develop next generation gene sequencing panel for companion diagnostic tests
26 August 2014 | By AstraZeneca
AstraZeneca announced that it has entered into a collaboration with gene sequencing company, Illumina, Inc., to develop its next generation sequencing platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio...
Abbott commences tender offer for all outstanding ordinary shares and American Depositary Shares of CFR Pharmaceuticals S.A.
26 August 2014 | By Abbott
Abbott announced that its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation ("ALH"), has commenced a tender offer...
Syrris launches new Atlas Cryo Reactor for ultra-low temperature synthesis
20 August 2014 | By kdm communications
Syrris is pleased to announce the launch of its state-of-the-art Atlas Cryo Reactor, providing exceptional cooling capability down to -80 °C...
Amgen names Elliott M. Levy, M.D., Senior Vice President, Global Development
20 August 2014 | By Amgen
Amgen announced that Elliott M. Levy, M.D., has been named senior vice president, Global Development, effective Sept. 8, 2014...
Novartis provides drug candidate compounds to TB Alliance
20 August 2014 | By Novartis
Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development for compounds to fight tuberculosis that have been discovered at the Novartis Institutes for Tropical Diseases...
Pfizer announces submission of palbociclib New Drug Application to the FDA
19 August 2014 | By Pfizer
Pfizer Inc. announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration for palbociclib...
Novo Nordisk accepts fine for violating disclosure obligation in Denmark
19 August 2014 | By Novo Nordisk
Novo Nordisk A/S has accepted a DKK 500,000 fine imposed by the Public Prosecutor in a suit filed by the Danish Financial Supervisory Authority and detailed in a press release issued by Novo Nordisk on 10 December 2013...
First patients enrolled in study to evaluate dabigatran etexilate after PCI with stenting
19 August 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that the first patients have been enrolled in the company’s new international phase III study, RE-DUAL PCI™...
